Novo Nordisk exits transdermal deal with Zosana for type 2 diabetes candidate

By Dan Stanton

- Last updated on GMT

Novo Nordisk is turning its back on the January 2014 licence agreement
Novo Nordisk is turning its back on the January 2014 licence agreement

Related tags Novo nordisk Diabetes mellitus Pharmacology

Novo Nordisk has ended a development partnership using Zosana Pharma’s microneedle patch system with its GLP-1 analogue semaglutide, currently being investigated in an oral formulation.

The Danish Pharma Giant entered into a licensing agreement with California-based Zosana in January 2014​ to develop a transdermal form of its human GLP-1 (Glucagon-Like Peptide-1) analogue, semaglutide, using Zosana’s proprietary microneedle patch system.

But after fifteen months, Novo Nordisk has notified its partner its intentions to discontinue the collaboration with all technology rights related to the field of GLP-1 returning to Zosana.

Zosana’s technology platform, the ZP Patch, uses drug coated microneedles on a patch the size of a US quarter to offer an alternative administration to injections for biopharmaceuticals and peptides. The transdermal system has been used in over 30 drug candidates, according to the company.

While Novo Nordisk spokesperson Nina Weimann would not divulge details of why it had pulled out of the deal when contacted, one reason could be the firm’s recent trial success of an oral formulation of the long-acting GLP-1 analogue.

In February, the firm announced positive Phase II results for OG217SC, with efficacy and safety of the oral formulation found to be comparable to that of subcutaneous semaglutide in a trial of around 600 people with type 2 diabetes.

At the time executive vice president and CSO Mads Krogsgaard Thomsen described this clinical proof as “an important milestone for oral peptide therapy within the field of diabetes.”

Related topics Drug Delivery Delivery technologies

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more